Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Toxoplasmosis Pipeline Drugs Market Report Overview

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever, and fatigue. Risk factors include HIV/AIDS, chemotherapy, and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

The toxoplasmosis pipeline products market research report provides comprehensive information on the therapeutics under development for toxoplasmosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for toxoplasmosis and features dormant and discontinued projects.

Toxoplasmosis Pipeline Products Market Segmentation by Targets

The key targets in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 and dihydrofolate reductase.

Toxoplasmosis Pipeline Products Market Analysis by Targets

Toxoplasmosis Pipeline Products Market Analysis by TargetsFor more target insights into the toxoplasmosis pipeline products market, download a free report sample

Toxoplasmosis Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 inhibitor and dihydrofolate reductase inhibitor.

Toxoplasmosis Pipeline Products Market Analysis by Mechanisms of Action

Toxoplasmosis Pipeline Products Market Analysis by Mechanisms of ActionFor more MoA insights into the toxoplasmosis pipeline products market, download a free report sample

Toxoplasmosis Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the toxoplasmosis pipeline products market are oral, intramuscular, intravitreal, and nasal. Oral accounted for the highest number of toxoplasmosis drugs in development in terms of RoA, in 2022.

Toxoplasmosis Pipeline Products Market Analysis by Routes of Administration

Toxoplasmosis Pipeline Products Market Analysis by Routes of AdministrationFor more RoA insights into the toxoplasmosis pipeline products market, download a free report sample

Toxoplasmosis Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the toxoplasmosis pipeline products market are small molecule, live attenuated vaccine, monoclonal antibody, mRNA vaccine, recombinant vector vaccine, and subunit vaccine. The small molecule is the leading molecule type in the toxoplasmosis pipeline products market.

Toxoplasmosis Pipeline Products Market Analysis by Molecule Types

Toxoplasmosis Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the toxoplasmosis pipeline products market, downloahttps://www.globaldata.com/store/talk-to-us/?report=3169199d a free report sample

Toxoplasmosis Pipeline Products Market - Competitive Landscape

Some of the leading companies in the toxoplasmosis pipeline products market are AbbVie Inc, GSK plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE.

Toxoplasmosis Pipeline Products Market Analysis by Companies

Toxoplasmosis Pipeline Products Market Analysis by CompaniesTo know more about the leading toxoplasmosis pipeline products market players, download a free report sample

Toxoplasmosis Pipeline Products Market Overview

Key Targets Calcium Dependent Protein Kinase 1 and Dihydrofolate Reductase
Key MoA Calcium Dependent Protein Kinase 1 Inhibitor and Dihydrofolate Reductase Inhibitor
Key RoA Oral, Intramuscular, Intravitreal, and Nasal
Key Molecule Type Small Molecule, Live Attenuated Vaccine, Monoclonal Antibody, mRNA Vaccine, Recombinant Vector Vaccine, and Subunit Vaccine
Leading Companies AbbVie Inc, GSK plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of toxoplasmosis.
  • The pipeline guide reviews pipeline therapeutics for toxoplasmosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in toxoplasmosis therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates toxoplasmosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for toxoplasmosis

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for toxoplasmosis.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the toxoplasmosis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
GSK plc
PGTx Ltd
Tiba Biotech LLC
Vaxinano SE

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toxoplasmosis – Overview

Toxoplasmosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Toxoplasmosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toxoplasmosis – Companies Involved in Therapeutics Development

AbbVie Inc

GSK plc

PGTx Ltd

Tiba Biotech LLC

Vaxinano SE

Toxoplasmosis – Drug Profiles

Monoclonal Antibodies for Ocular Toxoplasmosis – Drug Profile

Product Description

Mechanism Of Action

pyrimethamine – Drug Profile

Product Description

Mechanism Of Action

Recombinant Vector Vaccine for Protozoal Infection – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Toxoplasmosis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Toxoplasmosis – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDPK1 for Protozoal Infections – Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis [type II delta KU80 RH strain] vaccine – Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis vaccine – Drug Profile

Product Description

Mechanism Of Action

toxoplasmosis vaccine – Drug Profile

Product Description

Mechanism Of Action

Toxoplasmosis – Dormant Projects

Toxoplasmosis – Product Development Milestones

Featured News & Press Releases

Dec 07, 2021: FTC, States to recoup millions in relief for victims fleeced by ‘Pharma Bro’ scheme to illegally monopolize life-saving drug Daraprim

Apr 15, 2020: Oakrum Pharma announces the launch of Toxo Total Care patient services program to support Pyrimethamine 25mg tablets

Mar 31, 2020: Optime Care announces availability Of 25mg Pyrimethamine tablets for patients diagnosed with toxoplasmosis

Mar 11, 2020: Oakrum Pharma announces the launch of Pyrimethamine 25mg tablets in the United States

Feb 03, 2020: FDA grants approval of Daraprim drug’s first generic to Cerovene

Jan 27, 2020: FTC and NY Attorney General charge Vyera Pharmaceuticals, Martin Shkreli, and other defendants with anticompetitive scheme to protect a list-price increase of more than 4,000 percent for life-saving drug Daraprim

Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee

Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing

Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)

Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary

Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability

Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging

Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction

Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Toxoplasmosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Toxoplasmosis – Pipeline by AbbVie Inc, 2022

Toxoplasmosis – Pipeline by GSK plc, 2022

Toxoplasmosis – Pipeline by PGTx Ltd, 2022

Toxoplasmosis – Pipeline by Tiba Biotech LLC, 2022

Toxoplasmosis – Pipeline by Vaxinano SE, 2022

Toxoplasmosis – Dormant Projects, 2022

Toxoplasmosis – Dormant Projects, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Toxoplasmosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.